Navigation Links
CRESTOR(R) Reduced Risk of Blood Clots in the Veins
Date:3/29/2009

ORLANDO, Fla., March 29 /PRNewswire-FirstCall/ -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP). This analysis was presented today at the 58th Annual American College of Cardiology Scientific Sessions (ACC) in Orlando, Florida, and published simultaneously in the New England Journal of Medicine.

Venous thromboembolism, a serious and sometimes fatal condition, occurs when a blood clot forms in a vein. The most common form of VTE is deep vein thrombosis (DVT), which occurs in the 'deep veins' usually in the legs or pelvis. An embolism is created if the clot travels through the venous system. Blood clots lodging in the lungs are known as a pulmonary embolism (PE). Estimates suggest that at least 350,000 and as many as 600,000 Americans annually develop DVT/PE, and at least 100,000 deaths are thought to be related to these diseases each year.

Additional results of this secondary endpoint analysis of JUPITER showed rosuvastatin 20mg produced a significant 55% (p=0.004) reduction in the risk of DVT and a non-significant 23% reduction in PE (p=0.42).

"This is the first time a statin has been shown to reduce the risk of VTE in a randomized, prospective study," said Alex Gold, MD, Executive Director of Clinical Development, AstraZeneca US. "This result is in addition to the effect on cardiovascular events already demonstrated by CRESTOR in the primary analysis of JUPITER."

Rosuvastatin 20mg was well tolerated in nearly 9,000 patients during the course of the JUPITER study.

ABOUT JUPITER:

JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) was a
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Abbotts Phase III Sub-Group Analysis Shows Investigational TriLipix(TM) in Combination with CRESTOR(R) Improves Key Lipids in Patients with Mixed Dyslipidemia and Type 2 Diabetes
2. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
3. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
4. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
5. Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in New Study
6. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
7. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
8. Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation
9. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
10. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
11. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Medical Science ... As the key link between the medical device industry ... even more in the coming years as the device ... According to research by benchmarking firm, Best ... can gain an important edge is by harnessing new ...
(Date:12/22/2014)... 22, 2014 Research and Markets ( ... "US Self-monitoring Blood Glucose Market" report to their ... This market insight focuses on the developments in ... United States . Reimbursement analysis and the effects ... for more than 73 SMBG meters have been performed, ...
(Date:12/22/2014)... Cyberonics, Inc. (NASDAQ: CYBX ), a global leader ... today announced it will participate in the 33 rd ... in San Francisco . ... speak at 11:00 AM Pacific Time.  A live audio webcast ... Investor Relations link on the Cyberonics home page at ...
Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... BioStorage Technologies, Inc., a worldwide provider of long- ... chain logistics, will expand its European operations with the ... meters) full-service biorepository in Frankfurt, Germany. , BioStorage Technologies, ... growth plan to accommodate a rapidly growing list of ...
... PRINCETON, N.J., Oct. 21 PharmaNet Development Group, Inc., ... biotechnology, generic drug and medical device companies, today announced ... Trials Conference taking place at the World Trade Center ... , At the conference, top management will discuss ...
Cached Medicine Technology:BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility 2PharmaNet Development Group Management Participates in the 8th Annual Partnerships in Clinical Trials Conference in Rotterdam 2
(Date:12/25/2014)... -- Among early stage breast cancer patients who undergo ... percent will eventually develop leukemia as a result of ... comes from a review of more than 20,000 breast ... suggests that the risk for developing treatment-related leukemia, though ... "The frequency of bone marrow cancers such as ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as ... coolest mobile applications on the iOS, Android, and Windows markets. ... conducted the app review and shared with viewers how this ... The old saying goes, “A picture says a thousand words.” ... describe a single image, because each picture holds a unique ...
(Date:12/25/2014)... December 25, 2014 Parker & Sons, ... customer service and affordable quality regarding heating, cooling and ... recognition in 2014 by the “Queen of Clean” for ... earned an impressive reputation over the years for providing ... wide range of contractor services for both homeowners and ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected ... 30 years of practice experience in Dallas, Texas, has ... of dietary detoxification. The second study is scheduled to ... from test patients who just completed a 21-day detoxification ... in conducting the study, Dr. Casad said, "About 10 ...
(Date:12/24/2014)... TX (PRWEB) December 24, 2014 Dr. ... announced the expansion of his practice and med-spa with ... the practice’s growing list of cosmetic treatments and services. ... solution into the skin,” says Dr. Ho. “As a ... changes such as wrinkles, sun spots, discolorations or blemishes.” ...
Breaking Medicine News(10 mins):Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2
... treatment in adults as well as children , , MONDAY, ... off-label use of anticancer drugs in adults and children ... of that off-label use was for palliative care, say ... countries. , In off-label use, a drug is used ...
... DALLAS, Oct. 27 From Illinois to California, ... (Connecting About,Real Experiences) to find out about patients, ... visit. Hospitals participating in the initial,launch of this ... IL;,Clovis Community Medical Center in Clovis, CA; HealthONE ...
... 27 Accuray,Incorporated (Nasdaq: ARAY ), a global ... management is scheduled to present at the 19th,Annual Oppenheimer ... at 10:00 a.m. EST (7:00 a.m. PST.), A ... from the,investor relations page of the Company,s Web site ...
... New, dual action iron supplement pill with virtually no ... and nutritional benefits from ... iron to be available without prescription, CHICAGO, Oct. ... (http://www.alavenpharm.com ), an over-the-counter,iron supplement that offers both ...
... 5-Aminosalicylates Will Continue to be Used in ... Report from Decision Resources, WALTHAM, Mass., ... the,world,s leading research and advisory firms focusing ... Tanabe,s,Remicade is currently the leading biologic for ...
... to be presented Saturday, November 1, 2008 at this ... Francisco, California, October 31-November 4, SAN FRANCISCO, Oct. ... for a liver transplantation and 22,863 adults,who received transplantation ... that the increase in posttransplant,mortality caused by differences in ...
Cached Medicine News:Health News:Most Off-Label Cancer Drug Use for Palliative Care 2Health News:The Beryl Companies Launches CARE Calls Program in Five Hospitals Across U.S. 2Health News:Accuray Incorporated to Speak at Oppenheimer Healthcare Conference 2Health News:First-Ever Over-the-Counter Dual Action Iron Supplement Launched at the American Dietetic Association Conference in Chicago; Bifera to be Available in Select Stores in Early 2009 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2
The care package includes a spare motor, fuse, Spare Fluorescent Bulb, additional Vibratome Feather Blades, Specimen Adhesive, Specimen Mounting Blocks, and a Specimen Tray....
... (10 to 12) brain slices to be ... maintaining excellent viability. A mixture of 95% ... This initiates a circular flow and oxygen ... Slices remain viable for hours while awaiting ...
... provides a convenient reservoir of cooling water for the ... extended period of time or in a location which ... the hot side of the thermoelectric heat pump. ... is adequate to run the 900R for up to ...
Punch set for Advanced Tissue Arrayer, 0.6 mm...
Medicine Products: